Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anke Morgner

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Acta Neurochirurgica|November 10, 2012
Unusual clinico-pathological features in primary Hodgkin's lymphomas of the central nervous systemMarco Gessi, Klaus Kuchelmeister, Udo Kellner, et al.
Journal of Cancer Research and Clinical Oncology|October 29, 2024
Challenges in the treatment of soft-tissue plasmacytoma: a retrospective analysis of 120 patients with extramedullary multiple myelomaDominik Zolnowski, Simone Karp, Paul Warncke, et al.
Cancer Management and Research|March 26, 2026
Haploidentical Allogeneic Cell Transplantation in Relapsed/Refractory Multiple MyelomaJulia Frimmel, Anke Morgner, Claudia Brogsitter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 16, 2019
Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple MyelomaFrederick Fasslrinner, Friedrich Stölzel, Michael Kramer, et al.
Annals of Hematology|February 25, 2025
Is there still a place for autologous salvage transplantation in relapsed/refractory multiple myeloma in the era of novel therapies?Simone Karp, Karolin Trautmann-Grill, Paul Warncke, et al.
Haematologica|January 10, 2013
Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantationElisabeth Schorb, Benjamin Kasenda, Johannes Atta, et al.
Cancer Management and Research|February 25, 2022
Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of RelapseKatja Sockel, Friedrich Stölzel, Franziska Hönl, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2017
Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE TrialJan Moritz Middeke, Regina Herbst, Stefani Parmentier, et al.
Blood Advances|July 8, 2020
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpuraLinus A Völker, Jessica Kaufeld, Wolfgang Miesbach, et al.
Blood Advances|July 8, 2020
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTPLinus A Völker, Jessica Kaufeld, Wolfgang Miesbach, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Acta Neurochirurgica|November 10, 2012
Unusual clinico-pathological features in primary Hodgkin's lymphomas of the central nervous systemMarco Gessi, Klaus Kuchelmeister, Udo Kellner, et al.
Journal of Cancer Research and Clinical Oncology|October 29, 2024
Challenges in the treatment of soft-tissue plasmacytoma: a retrospective analysis of 120 patients with extramedullary multiple myelomaDominik Zolnowski, Simone Karp, Paul Warncke, et al.
Cancer Management and Research|March 26, 2026
Haploidentical Allogeneic Cell Transplantation in Relapsed/Refractory Multiple MyelomaJulia Frimmel, Anke Morgner, Claudia Brogsitter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 16, 2019
Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple MyelomaFrederick Fasslrinner, Friedrich Stölzel, Michael Kramer, et al.
Annals of Hematology|February 25, 2025
Is there still a place for autologous salvage transplantation in relapsed/refractory multiple myeloma in the era of novel therapies?Simone Karp, Karolin Trautmann-Grill, Paul Warncke, et al.
Haematologica|January 10, 2013
Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantationElisabeth Schorb, Benjamin Kasenda, Johannes Atta, et al.
Cancer Management and Research|February 25, 2022
Allogeneic Stem Cell Transplantation with Sequential Melphalan-Based Conditioning in AML: Residual Morphological Blast Count Determines the Risk of RelapseKatja Sockel, Friedrich Stölzel, Franziska Hönl, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 22, 2017
Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE TrialJan Moritz Middeke, Regina Herbst, Stefani Parmentier, et al.
Blood Advances|July 8, 2020
Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpuraLinus A Völker, Jessica Kaufeld, Wolfgang Miesbach, et al.
Blood Advances|July 8, 2020
ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTPLinus A Völker, Jessica Kaufeld, Wolfgang Miesbach, et al.
Pageof 2